# Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

> **NCT00170001** · NA · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 500 (actual)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** Nexium
- **DRUG:** Sugar Pill

## Key facts

- **NCT ID:** NCT00170001
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2011-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170001, "Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00170001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*